WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H527408
CAS#: 1646857-24-0
Description: BTA-9881, also known as AZD-9639 and MEDI-564, is a viral fusion protein inhibitor potentially for the treatment of respiratory syncytial virus infection.
Hodoodo Cat#: H527408
Name: BTA-9881
CAS#: 1646857-24-0
Chemical Formula: C21H15ClN4O2
Exact Mass: 390.09
Molecular Weight: 390.827
Elemental Analysis: C, 64.54; H, 3.87; Cl, 9.07; N, 14.34; O, 8.19
Synonym: BTA-9881; BTA 9881; BTA9881; AZD-9639; AZD9639;AZD 9639; MEDI-564; MEDI564; MEDI 564;
IUPAC/Chemical Name: (S)-9b-(4-chlorophenyl)-1-nicotinoyl-1,2,3,9b-tetrahydro-5H-imidazo[1',2':1,2]pyrrolo[3,4-c]pyridin-5-one
InChi Key: QZSZPSDRJPPZDZ-OAQYLSRUSA-N
InChi Code: InChI=1S/C21H15ClN4O2/c22-16-5-3-15(4-6-16)21-18-13-24-9-7-17(18)20(28)26(21)11-10-25(21)19(27)14-2-1-8-23-12-14/h1-9,12-13H,10-11H2/t21-/m1/s1
SMILES Code: O=C1N2[C@@](C3=C1C=CN=C3)(C4=CC=C(Cl)C=C4)N(C(C5=CC=CN=C5)=O)CC2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | BTA-9881, also known as AZD-9639 and MEDI-564, is a viral fusion protein inhibitor potentially for the treatment of respiratory syncytial virus infection. |
In vitro activity: | TBD |
In vivo activity: | TBD |
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 0.0 | 0.00 |
The following data is based on the product molecular weight 390.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | TBD |
In vitro protocol: | TBD |
In vivo protocol: | TBD |
1: Bonfanti JF, Roymans D. Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection. Curr Opin Drug Discov Devel. 2009 Jul;12(4):479-87. Review. PubMed PMID: 19562644.